Toll Free: 1-888-928-9744
Published: Apr, 2014 | Pages:
40 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
CEL-SCI Corporation - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'CEL-SCI Corporation - Product Pipeline Review - 2014', provides an overview of the CEL-SCI Corporation's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of CEL-SCI Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of CEL-SCI Corporation including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of CEL-SCI Corporation's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the CEL-SCI Corporation's pipeline products Reasons to buy - Evaluate CEL-SCI Corporation's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of CEL-SCI Corporation in its therapy areas of focus - Identify new drug targets and therapeutic classes in the CEL-SCI Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of CEL-SCI Corporation and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of CEL-SCI Corporation - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of CEL-SCI Corporation and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 CEL-SCI Corporation Snapshot 5 CEL-SCI Corporation Overview 5 Key Information 5 Key Facts 5 CEL-SCI Corporation - Research and Development Overview 6 Key Therapeutic Areas 6 CEL-SCI Corporation - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 CEL-SCI Corporation - Pipeline Products Glance 13 CEL-SCI Corporation - Late Stage Pipeline Products 13 Phase III Products/Combination Treatment Modalities 13 CEL-SCI Corporation - Clinical Stage Pipeline Products 14 Phase I Products/Combination Treatment Modalities 14 CEL-SCI Corporation - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 CEL-SCI Corporation - Drug Profiles 16 Leukocyte Interleukin Injection 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 LEAPS-H1N1-DC 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 CEL-1000 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 CEL-2000 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 J-HER Vaccine For Breast Cancer 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 CEL-SCI Corporation - Pipeline Analysis 24 CEL-SCI Corporation - Pipeline Products by Target 24 CEL-SCI Corporation - Pipeline Products by Molecule Type 25 CEL-SCI Corporation - Recent Pipeline Updates 26 CEL-SCI Corporation - Company Statement 36 CEL-SCI Corporation - Locations And Subsidiaries 38 Head Office 38 Appendix 39 Methodology 39 Coverage 39 Secondary Research 39 Primary Research 39 Expert Panel Validation 39 Contact Us 40 Disclaimer 40
List of Tables CEL-SCI Corporation, Key Information 5 CEL-SCI Corporation, Key Facts 5 CEL-SCI Corporation - Pipeline by Indication, 2014 7 CEL-SCI Corporation - Pipeline by Stage of Development, 2014 9 CEL-SCI Corporation - Monotherapy Products in Pipeline, 2014 10 CEL-SCI Corporation - Partnered Products in Pipeline, 2014 11 CEL-SCI Corporation - Partnered Products/ Combination Treatment Modalities, 2014 12 CEL-SCI Corporation - Phase III, 2014 13 CEL-SCI Corporation - Phase I, 2014 14 CEL-SCI Corporation - Preclinical, 2014 15 CEL-SCI Corporation - Pipeline by Target, 2014 24 CEL-SCI Corporation - Pipeline by Molecule Type, 2014 25 CEL-SCI Corporation - Recent Pipeline Updates, 2014 26
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.